Welcome to our dedicated page for Mirion Technologies news (Ticker: MIR), a resource for investors and traders seeking the latest updates and insights on Mirion Technologies stock.
Overview
Mirion Technologies Inc is a globally recognized provider of advanced nuclear safety, radiation detection, and medical diagnostics solutions. For over 50 years, the company has delivered precision products and services designed to safely harness and manage ionizing radiation across critical markets. With a strong reputation for protecting people, property, and the environment, Mirion stands as an essential partner in applications where accurate radiation measurement and monitoring are a matter of safety and progress.
Business Segments
Mirion Technologies is uniquely structured through two primary business segments:
- Nuclear & Safety: This segment focuses on radiation safety, measurement, and analysis for the nuclear energy sector, research laboratories, defense, and homeland security. It underpins industries that rely on secure operations and rigorous safety protocols in environments exposed to nuclear and radiological hazards.
- Medical: Dedicated to enhancing the quality and safety of cancer care and medical diagnostics, this division supports critical applications in healthcare. The products and services developed here directly improve practitioner safety and patient care through advanced radiation processing and management technologies.
Products and Services
Mirion provides a comprehensive portfolio that includes radiation detection instruments, monitoring systems, and sophisticated analytical software. The company’s solutions are designed not only to detect ionizing radiation but also to analyze and monitor its effects in real time. These capabilities are vital for ensuring operational safety in a wide array of environments, from medical facilities to research laboratories and industrial sites.
Global Presence and Industry Impact
With facilities strategically located across Europe, Asia, and North America, Mirion Technologies has established a robust global footprint. Its headquarters in the San Francisco Bay Area serve as a hub for innovation and operational excellence. The company’s longevity and consistent performance in high-stakes industries underscore its importance as an industry stalwart, trusted by customers worldwide.
Market Position and Competitive Landscape
Mirion occupies a critical niche within the nuclear and medical safety sectors. Its sophisticated product line and strategic segmentation allow it to address very specific industry needs. In a competitive landscape populated with companies offering radiation measurement and safety solutions, Mirion differentiates itself through decades of technical expertise, global reach, and a steadfast commitment to quality. The company’s balanced approach to innovation and safety ensures it remains an essential component in the ecosystem of technologies that mitigate radiological risks.
Expertise and Technological Innovation
Mirion Technologies places a high premium on technological rigor and expert craftsmanship. Its solutions are developed through extensive research and are continuously refined to meet the strictest safety standards. The depth of its engineering expertise is evident in every aspect of its product offerings, supporting industries that depend on reliable, accurate, and timely radiation measurements.
Conclusion
Overall, Mirion Technologies Inc stands as a profound example of operational excellence within the critical fields of radiation safety and medical diagnostics. Its dual-segment strategy caters to distinct but equally important markets, reinforcing the company’s longstanding commitment to protecting lives and advancing technology. For stakeholders seeking a clear understanding of the company, Mirion represents a well-balanced blend of history, innovation, and technical precision.
Mirion Technologies, Inc. (NYSE: MIR) has entered a definitive agreement to sell the physical medicine assets of Biodex Medical Systems, Inc. to Salona Global Medical Device Corporation for $5 million in cash and up to $3 million in deferred cash payments based on asset performance. These assets generated approximately $18 million in revenue with a gross margin of 30% in the last year. The deal is expected to close on December 31, 2022, allowing Mirion to focus on its core mission regarding ionizing radiation.
Mirion Technologies (MIR) reported third-quarter revenues of $160.9 million, an 11.5% increase from $144.3 million year-over-year. Despite this growth, the company faced a GAAP net loss of $50.4 million compared to a loss of $46.7 million in the prior year. Adjusted EBITDA decreased slightly to $30.8 million. Mirion anticipates organic adjusted revenue growth of 4% to 6% for 2022 alongside adjusted EBITDA guidance of $160 million to $170 million and adjusted EPS of $0.37 to $0.41. Year-to-date order growth stood at 23% with a $726 million backlog.
Mirion Technologies (NYSE: MIR) announced that CEO Thomas Logan and CFO Brian Schopfer will present at the 2022 Baird Industrial Conference in Chicago, IL. The presentation is scheduled for 11:50 AM ET on Thursday, November 10, 2022. A live webcast will be available at this link and will be archived for two weeks post-event.
Mirion is a premier provider of solutions for the nuclear, defense, medical, and research sectors, employing around 2,800 people globally.
Mirion Technologies (NYSE: MIR) announced it will release its financial results for Q3 2022 on November 1, 2022, after market close. The company will hold a conference call at 4:30 pm ET on the same day to discuss the results. Interested participants can join the call by dialing 1-877-407-9208 or 1-201-493-6784, or via a live webcast on the company's investor relations website.
Mirion is a leading provider of radiation detection and monitoring solutions, headquartered in Atlanta, GA, and operates in 13 countries with approximately 2,800 employees.
On October 21, 2022, Sun Nuclear, a subsidiary of Mirion Technologies (NYSE: MIR), announced its participation in the ASTRO Annual Meeting, showcasing its enhanced Quality Management portfolio. Key exhibits include the SunCHECK Platform and the new SunSCAN 3D System, designed for precise dosimetry and efficient workflows in radiation therapy. Sun Nuclear emphasizes its commitment to patient safety, supporting over 1,600 global clinical users with advanced QA solutions. The event runs from October 23-25, 2022, in San Antonio, Texas, where attendees can participate in demonstrations and networking sessions.
Sun Nuclear, a subsidiary of Mirion Technologies (NYSE: MIR), announced the development of new Quality Management solutions in collaboration with Accuray for the Radixact® System with Synchrony®. These innovations will be showcased at the ASTRO Annual Meeting from October 23-25, 2022. Key offerings include the Enhanced Dynamic Platform, designed for precise tumor treatment, and the MotionCHECK™ 3D System, enhancing tumor tracking capabilities. These tools aim to improve patient safety and quality assurance in advanced radiation therapy.
Mirion Technologies has appointed Michael Rossi as the new President of Mirion Medical, reporting directly to CEO Tom Logan. Rossi, with extensive experience from Novartis and other companies, aims to leverage his expertise in nuclear medicine to boost organic and inorganic growth within the company. Logan expressed confidence in Rossi's leadership abilities, highlighting the exciting growth opportunities ahead for Mirion. The company, headquartered in Atlanta, is a leading provider of radiation detection and analysis solutions, employing around 2,800 personnel across 13 countries.
Mirion Technologies, Inc. (NYSE: MIR) announced that its subsidiary, Sun Nuclear, achieved ISO/IEC 27001:2013 certification for its information security management system. This certification confirms Sun Nuclear's compliance with international standards for managing sensitive data across its facilities in the U.S., Germany, and the Netherlands. It also applies to the SunCHECK® Platform, enhancing software reliability and security. This distinction positions Sun Nuclear as a leading QA provider in the Radiation Oncology field, reinforcing its commitment to customer data protection.
Mirion Technologies, Inc. (NYSE: MIR) announces the appointment of Dr. Sheila Rege, M.D. to its Board of Directors, succeeding Mr. Christopher Warren. Dr. Rege, a board-certified radiation oncologist with over 30 years of experience, will support Mirion's strategy to enhance its Medical segment, aiming for 50% of total revenue. Chairman Lawrence D. Kingsley expressed confidence in her contributions to the company’s growth. Chris Warren leaves with commendations for his role in Mirion's evolution since 2015, emphasizing strong demand momentum in the market.
Sun Nuclear, a subsidiary of Mirion Technologies (NYSE: MIR), announced that its ATOM® Phantom product line will participate in NASA's historic Artemis I mission, set to launch on August 29, 2022. Two custom ATOM Phantoms, named Helga and Zohar, will measure potential radiation exposure for astronauts aboard the Orion spacecraft. This mission marks an important step for human exploration of the Moon and Mars. The ATOM Phantoms, designed to simulate human anatomy, will assist in understanding the effects of space radiation, particularly on female astronauts.
FAQ
What is the current stock price of Mirion Technologies (MIR)?
What is the market cap of Mirion Technologies (MIR)?
What does Mirion Technologies Inc specialize in?
How is the company structured?
Which industries does Mirion serve?
What types of products and services does Mirion offer?
How long has Mirion been in operation?
What is the global presence of Mirion Technologies?
How does Mirion differentiate itself from competitors?
What role does Mirion play in the medical sector?
